EUVIMEDSkopri EUVIMED
Beobachtungsstudie

Obinutuzumab in untreated primary membranous nephropathy: An observational case series

Jinling Hao iD, Jing Wang, Pan Zhou, Rong Xu, Xiaoli Chen

Nephrology · 2024-11 · 29 (11) · 709-716

DOI: 10.1111/nep.14331 ↗

At a glance

Beobachtungsstudie in Nephrology, published online on 2024-06-03. Written by Jinling Hao and 4 co-authors. Institution: Department of Nephrology, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China. Major MEDLINE topics: Glomerulonephritis, Membranous, Antibodies, Monoclonal, Humanized, Remission Induction, Receptors, Phospholipase A2. Cited 11 times so far (Crossref); 24 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

As an initial treatment for primary membranous nephropathy (PMN), there remains a significant proportion of patients for whom rituximab is not fully effective. Here, we aimed to assess the effectiveness and safety of obinutuzumab as initial treatment in patients with PMN.

Methods

In this observational case series, patients diagnosed with PMN and treated with obinutuzumab as initial treatment were included. Treatment response was assessed by 24‐h urine total protein (24 h UTP) and serum albumin, and immunologic remission was assessed by phospholipase A2 receptor (PLA2R) antibodies.

Results

Twelve patients with PMN receiving obinutuzumab as initial treatment were included. Over 6 months, a statistically significant reduction in 24 h UTP levels ( p = 0.003) and an increase in serum albumin levels were observed ( p < 0.001). By the 6‐month follow‐up, two patients (16.7%) achieved complete remission, eight (66.6%) reached partial remission, and two (16.7%) showed no remission. Immunological remission was observed in 44.4% of evaluable patients ( n = 9) after 3 months, increasing to 100% (6/6) at 6 months. Except for cases 1, 2, and 3, the total B cell counts in the remaining patients fell to less than 5 cells/μL before the administration of the second dose of obinutuzumab, including seven patients with counts as low as 0 cells/μL. Mild to moderate treatment‐related adverse events (TRAEs) were reported in 58.3% (7/12) of the patients. No serious TRAEs were reported.

Conclusions

Obinutuzumab demonstrates promising potential as an initial treatment for PMN, with good effectiveness and a manageable safety profile. Further large‐scale prospective studies are needed to confirm these findings. image

Subjects

MeSH terms (MEDLINE)

Glomerulonephritis, MembranousAntibodies, Monoclonal, HumanizedRemission InductionReceptors, Phospholipase A2HumansMaleFemaleMiddle AgedTreatment OutcomeAdultAgedProteinuriaTime FactorsSerum Albumin, Human

Author keywords

B‐cell targeted therapyobinutuzumabphospholipase A2 receptorprimary membranous nephropathyremission rate

Substances

Antibodies, Monoclonal, HumanizedobinutuzumabReceptors, Phospholipase A2PLA2R1 protein, humanSerum Albumin, Human

Authors and institutions

  • Department of Nephrology, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China.
  • Department of Nutrition, Taiyuan Hospital of Peking University First Hospital, Taiyuan, Shanxi, China.
  • Department of Nephrology, Peking University First Hospital, Beijing, China.

ORCID profiles: Jinling Hao

Cite

APA

Hao, J., Wang, J., Zhou, P., Xu, R., & Chen, X. (2024). Obinutuzumab in untreated primary membranous nephropathy: An observational case series. Nephrology, 29(11), 709-716. https://doi.org/10.1111/nep.14331

Vancouver

Hao J, Wang J, Zhou P, Xu R, Chen X. Obinutuzumab in untreated primary membranous nephropathy: An observational case series. Nephrology. 2024;29(11):709-716. doi:10.1111/nep.14331

BibTeX
@article{Hao2024,
  author = {Hao, Jinling and Wang, Jing and Zhou, Pan and Xu, Rong and Chen, Xiaoli},
  title = {Obinutuzumab in untreated primary membranous nephropathy: An observational case series},
  journal = {Nephrology},
  year = {2024},
  volume = {29},
  number = {11},
  pages = {709--716},
  doi = {10.1111/nep.14331}
}
Start for free →